PFIZERPfizer Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-09-11 (delayed ~30 min in market hours)
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on PFIZER — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • ROE: 17.2%
- • ROCE: 19.8%
- • Debt/Equity: 0.02
- • Trend strength (ADX): 28
- • Volume: 1.8x 20-day average
- • Volume trend: 1.7x baseline
Bull case
- • ROE: 17.2%
- • ROCE: 19.8%
- • Debt/Equity: 0.02
- • Trend strength (ADX): 28
Bear case
- • Revenue growth: 6.3% YoY
- • Profit growth: -39.6% YoY
- • RSI: 18
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Revenue growth: 6.3% YoY
- • Profit growth: -39.6% YoY
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹111.09). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.